Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
Boehringer: what’s in and what’s out?
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
Microbiome make or break time for MaaT Pharma
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Astra starts a pivotal lung cancer combo
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
